Tysabri: a few answers

August 2006
Inside MS;Aug/Sep2006, Vol. 24 Issue 4, p38
Academic Journal
The article provides information on Tysabri drug. Tysabri is prescribed for people with relapsing multiple sclerosis who have no other illnesses that weaken the immune system. People taking the drug are at risk of developing progressive multifocal leukoencephalopathy. The annual wholesale price of the drug is $28,400. Tysabri should be covered by Medicare Part B because it is administered at a medical facility.


Related Articles

  • An approach to natalizumab hypersensitivity: a case series of induction of tolerance. Camacho-Halili, Marie; George, Roxanne; Gottesman, Malcolm; Davis-Lorton, Mark // Multiple Sclerosis Journal;02/01/2011, Vol. 17 Issue 2, p250 

    Induction of tolerance protocols have been applied successfully to manage allergic reactions to many medications. Hypersensitivity reactions to natalizumab (TYSABRI® ) have been recognized as a growing problem. In circumstances where a hypersensitivity reaction to a medication has occurred,...

  • Natalizumab: state of the art and open questions. Comi, G. // Neurological Sciences;Jan2011, Vol. 31, p313 

    No abstract available.

  • First oral therapies for multiple sclerosis anticipated. Hughes, Bethan // Nature Reviews Drug Discovery;Nov2009, Vol. 8 Issue 11, p831 

    The article assesses the efficacy of several oral drugs in development for the treatment of relapsing-remitting multiple sclerosis. Cladribine and fingolimod have shown good efficacy. Alemtuzumab, a humanized monoclonal antibody, offers key advantages in terms of convenience to patients. Side...

  • Natalizumab.  // Reactions Weekly;10/4/2008, Issue 1222, p25 

    The article describes the case of a 58-year-old woman who experienced autoimmune thrombocytopenia during treatment with natalizumab for relapsing-remitting multiple sclerosis. It references a study by D. Jones et al, presented at the 2008 World Congress on Treatment and Research in Multiple...

  • Natalizumab.  // Reactions Weekly;10/4/2008, Issue 1222, p25 

    The article describes the case of seven patients with multiple sclerosis who developed clinical relapses within 24 hours of their first natalizumab dose. It references a study by D. Centonze et al, published in the September 2008 issue of the journal "Multiple Sclerosis." As stated, two men and...

  • Daclizumab.  // Reactions Weekly;10/4/2008, Issue 1222, p14 

    The article describes the case of a 34-year-old woman with relapsing-remitting multiple sclerosis who started taking daclizumab and interferon-β as part of a study. On her ninth dose, she developed a non-pruritic generalised erythematous papular rash. Biopsy results showed granulomatous foci...

  • Daclizumab.  // Reactions Weekly;10/4/2008, Issue 1222, p14 

    The article describes the case of a 42-year-old woman with multiple sclerosis who developed central nervous system (CNS) vasculitis while undergoing daclizumab monotherapy. The woman participated in a phase II trial of the drug and during the trial she achieved an optimal response but she...

  • Subcutaneous administration of alemtuzumab in patients with highly active multiple sclerosis. Perumal, Jai S; Foo, Farng; Cook, Perry; Khan, Omar // Multiple Sclerosis Journal;Aug2012, Vol. 18 Issue 8, p1197 

    Alemtuzumab is an anti-CD52 monoclonal antibody with remarkable efficacy in relapsing multiple sclerosis (MS). In clinical trials and off-label use in MS, alemtuzumab has been administered intravenously (IV). Alemtuzumab is approved for chronic lymphoid leukemia as IV. Oncology guidelines...

  • Alemtuzumab Use in Clinical Practice: Recommendations from European Multiple Sclerosis Experts. Berger, Thomas; Elovaara, Irina; Fredrikson, Sten; McGuigan, Chris; Moiola, Lucia; Myhr, Kjell-Morten; Oreja-Guevara, Celia; Stoliarov, Igor; Zettl, Uwe; Zettl, Uwe K // CNS Drugs;Jan2017, Vol. 31 Issue 1, p33 

    Alemtuzumab (Lemtradaâ„¢) is a humanized monoclonal antibody approved in more than 50 countries. Within the European Union, alemtuzumab is indicated for the treatment of adult patients with relapsing-remitting multiple sclerosis (RRMS) with active disease defined by clinical or imaging...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics